Tesaro wins FDA OK for an IV version of chemo drug, launches discovery deal with Evotec

Mary Lynne Hedley, Tesaro

→ The FDA has approved an IV version of the already OK’d drug Varubi, used to treat the nausea and vomiting triggered by chemotherapy. “The majority of NK-1 receptor antagonist doses are administered intravenously in the U.S., and with the introduction of Varubi IV, we now offer healthcare providers a unique, easy-to-use option that fits well into standard operating practices of a chemotherapy clinic or hospital,” said Tesaro president Mary Lynne Hedley.

Evotec AG and Tesaro launched a three-year discovery deal to track down and develop novel small molecule product candidates against an undisclosed immuno-oncology target.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has offered GSK a key endorsement for their new shingles vaccine Shingrix. A slight majority backed Shingrix over Merck’s long established rival Zostavax, which is expected to give up a big share of the market now.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Chief Medical Officer
Skyhawk Therapeutics Waltham, MA
Chief of Staff, North America
Ipsen Biopharmaceuticals Cambridge, MA
Senior Director, NA Digital Customer Interaction
Ipsen Biopharmaceuticals Cambridge, MA
Manufacturing Associate – Upstream
Molecular Templates Austin, TX
Scientist, Process Development
Molecular Templates Austin, TX
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Quality Control (QC) Associate
Molecular Templates Austin, TX

Visit Endpoints Careers ->